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Mu Opioid Receptor Desensitization in Inflammatory Pain 
Matthew Bredder, Nicolas Massaly, Adie Wilson-Poe, Jose Moron-Concepcion 
Washington University in St. Louis – Department of Anesthesiology – Biology, Psychology Class of 2017 
Due to the epidemic level of opioid overdose deaths in the United States, improving the treatment of chronic pain has become a pressing concern. Opioid treatments such as fentanyl 
and morphine activate mu opioid receptors (MORs), causing an increase in dopamine release. Long term use of opioids, even as prescribed by a physician, can desensitize the MORs 
and lead to the appearance of withdrawal symptoms when the receptors are no longer stimulated. Since pain increases endogenous opioid release, we hypothesized that this increase 
may cause MOR desensitization and the appearance of withdrawal syndrome upon blockade of MORs, as seen in long term opioid use.  
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Additional research must be conducted to assess whether chronic pain increases the likelihood of developing opioid dependence. Specifically, self administration experiments 
provide a useful model for drug use in humans.  Animals in pain can be compared to control animals to show the behavioral differences between these groups. To measure 
motivation, rats are trained to press a lever to receive a food or drug reward. For the condition of pain, a decrease in motivation, often determined by the breakpoint in a progressive 
ratio schedule, would provide further evidence of decreased DA, as DA is instrumental in motivation and reward. Dose-response exposes the animals to a range of drug doses and 
plots the number of injections to show which dose was preferred. A positively shifted dose-response curve for animals in pain would support our finding of MOR desensitization, as 
the most rewarding dose was higher than for controls. In escalation, animals are given access to self administer drugs, in this case opioids, over an extended period. A sharp 
increase of intake models the development of drug abuse or dependence in humans. If escalation were to occur more quickly for animals in pain, this would indicate an increased 
risk of developing opioid dependence. 
 
 
The number of WDS experienced for each treatment group at each observation 
time are displayed in Figure A. A two-way ANOVA (treatment X time) revealed a 
main effect of treatment (F₂,₈₀ = 13.11, p < 0.001), no effect of tim  (F₄,₈₀ = 0.53, p 
= 0.72), and no significant interaction between treatment and time (F₈,₈₀ = 0.67, p 
= 0.71). These results indicate that the number of WDS depended on treatment, 
rather than time, and that the effect of treatment did not vary with time. Post-hoc 
analysis using a Tukey HSD (honest significant difference) test was run for 
pairwise comparisons. The CTAP-CFA group showed a significant increase in the 
number of WDS compared to the Sal-CFA group (p < 0.001) and the CTAP-Sal 
group (p < 0.001). Plots of the residuals, in Figure B, demonstrated a good fit of 
this model to the data. The Residuals vs Fitted plot shows no pattern around the 
zero line, while the Normal Q-Q plot follows the regression line fairly well, except 
for a few points trailing off. 
To test this hypothesis, we bilaterally inserted 
cannulae into the VTA, a brain region 
containing MORs and involved in reward 
processing, of Sprague-Dawley and Long-
Evans rats of both sexes, Figure A. Complete 
Freund’s Adjuvant (CFA) was used to induce 
chronic inflammatory pain, Figure C. CTAP, a 
highly selective MOR antagonist, was injected 
via cannulae to induce withdrawal symptoms, 
Figure B. Each animal experienced one of 
three conditions: CFA + CTAP, Saline + CTAP, 
or CFA + Saline. Wet dog shakes (WDS), a 
common sign of opioid withdrawal in rats, 
were measured in five minute periods one, 
two, three, five, and eight hours after CTAP 
injection.  
 
Why were wet dog shakes used to measure 
withdrawal syndrome? 
•  Well established opioid withdrawal 
symptom in rats 
•  Discrete, can easily quantify withdrawal 
•  Easy to observe – high inter-observer 
reliability 
•  Long time course for experiment, different 
experimenters observed the animals 
•  Requires no special equipment 
 
A significant increase in WDS was observed for male Sprague-
Dawley rats in the CTAP-CFA group compared to each of the 
other conditions. This increase in WDS may be explained by 
chronic inflammatory pain causing MOR desensitization in the 
same manner as long term exposure to opioids does. 
 
Furthermore, pain-induced MOR desensitization may increase 
the likelihood of developing opioid dependence. As opioids, 
like morphine and fentanyl, are considered the gold standard 
for pain treatment, patients may experience the combined risk 
of exposure to an addictive substance and a dysregulated 
response to that substance.  
 
More work investigating how pain impacts opioid dependent 
dopamine release is necessary and may ultimately lead to 
improved pain treatment and decreased opioid dependence. 
In Figure A, reduced dopamine 
(DA) release in the nucleus 
accumbens (NAc) was seen in 
the condition of inflammatory 
pain when selective MOR 
a g o n i s t  D A M G O  w a s 
administered in the ventral 
t e g m e n t a l  a r e a ( V TA ) . 
Furthermore, autoradiography 
in Figure B showed reduced 
MOR function in the VTA for 
animals experiencing pain 
compared to controls. The 
circled regions indicate the 
approximate location of the 
VTA, while warmer colors 
(orange and red) signify greater 
function than cooler colors (light 
and dark green). These results 
indicate the importance of MOR 
funct ion on VTA neurons 
projecting to the NAc in DA 
release and the effect of 
inflammatory pain on this 
system. 
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Binding of an agonist at the MOR inhibits tonic GABA release, 
leading to disinhibition of dopaminergic neurons projecting to the 
NAc and thus an increase in DA (Figure A). In animals experiencing 
inflammatory pain, as in opioid dependent rats, the MORs are 
desensitized. We hypothesized that endogenous opioid release in 
chronic inflammatory pain may lead to dramatic changes in opioid 
sensitivity. We chose to test the appearance of withdrawal signs by 
injecting a selective MOR antagonist: CTAP. 
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